1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 15:CLASS

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1 C,H,S,N

G2 X,C,H,O

Structure attributes must be viewed using STN Express query preparation.

=> s l8 full
GENERIC GROUP NOT VALID HERE
Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.
2. An Ak node attached to another Ak node.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	431.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-36.50

FILE 'REGISTRY' ENTERED AT 14:19:15 ON 03 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAY 2007 HIGHEST RN 934214-84-3
DICTIONARY FILE UPDATES: 2 MAY 2007 HIGHEST RN 934214-84-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l8 full
GENERIC GROUP NOT VALID HERE
Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.
2. An Ak node attached to another Ak node.

=>
Uploading C:\Program Files\Stnexp\Queries\519197.str





chain nodes :
11 15
ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
13
chain bonds :
3-11 4-13 5-15
ring bonds :
1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10
exact/norm bonds :
3-11 4-13 5-15
normalized bonds :
1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10

G1:C,H,S,N

G2:X,C,H,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 15:Atom

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



G1 C,H,S,N

G2 X,C,H,O

Structure attributes must be viewed using STN Express query preparation.

=> s l9 full
FULL SEARCH INITIATED 14:20:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 747170 TO ITERATE

100.0% PROCESSED 747170 ITERATIONS 85771 ANSWERS
SEARCH TIME: 00.00.06

L10 85771 SEA SSS FUL L9

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.00	604.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-36.50

FILE 'CA' ENTERED AT 14:21:01 ON 03 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Apr 2007 VOL 146 ISS 19
FILE LAST UPDATED: 26 Apr 2007 (20070426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l10
L11        4344 L10

=> s l11 an dpy<2002
MISSING OPERATOR L11 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l11 an py<2002
MISSING OPERATOR L11 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l11 and py<2002
      21031248 PY<2002
L12        3529 L11 AND PY<2002

=> d his

     (FILE 'HOME' ENTERED AT 14:15:14 ON 03 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 14:15:29 ON 03 MAY 2007
L1              STRUCTURE UPLOADED
L2             50 S L1 SAM
L3         254513 S L1 FULL

     FILE 'CA' ENTERED AT 14:15:57 ON 03 MAY 2007
L4         70217 S L3
L5         56103 S L4 AND PY<2002
L6         29448 S PDE? OR PHOSPHODIESTERASE?
L7           109 S L6 AND L5

     FILE 'REGISTRY' ENTERED AT 14:18:44 ON 03 MAY 2007
L8              STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:19:15 ON 03 MAY 2007
L9              STRUCTURE UPLOADED
L10        85771 S L9 FULL

     FILE 'CA' ENTERED AT 14:21:01 ON 03 MAY 2007
```

```
L11         4344 S L10
L12         3529 S L11 AND PY<2002

=> s l12 and l6
L13            6 L12 AND L6

=> d ibib abs fhitstr 1-6
```

L13 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 137:279361 CA
TITLE: Preparation of nitrosated and nitrosylated α-adrenergic receptor antagonists for the treatment of sexual dysfunction
INVENTOR(S): Garvey, David S.; Saenz De Tejada, Inigo; Gaston, Ricky D.; Khanapure, Subhash P.; Shelekhin, Tatiana E.; Wang, Tiansheng
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of U.S. 6,294,517.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002143007	A1	20021003	US 2002-146671	20020516
US 5932538	A	19990803	US 1996-595732	19960202
<--				
US 5994294	A	19991130	US 1996-714313	19960918
<--				
US 6294517	B1	20010925	US 1998-145143	19980901
<--				
US 2005187222	A1	20050825	US 2005-109761	20050420
PRIORITY APPLN. INFO.:			US 1996-595732	A2 19960202
			US 1996-714313	A2 19960918
			US 1998-145143	A2 19980901
			WO 1997-US1294	A2 19970128
			US 1999-387724	A1 19990901
			US 2002-146671	A1 20020516

OTHER SOURCE(S): MARPAT 137:279361
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I, II, III, etc. [R1 = H, alkoxy; R2 = NMe(CH2)aNHCORc, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, etc.; a= 2, 3; Rc = heterocyclic, alkyl, hydroxyalkyl, etc.; D = NO, NO2, etc.; R3 = CH2N(4-MeC6H4)(3-DOC6H4), CH2Ph, 2-methoxy-1,4-benzodioxin-2-yl, etc.; D1 = H or D with the proviso that D1 must be D if there is no other D in the compound; R4 = H, D, CORd; R5 = H, C(O)ORk, etc.; Rd = H, alkyl, cycloalkyl, etc.; Rk = H, alkyl] were prepared For example, nitrosylation of thiol IV

L13 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN (Continued)
(X = H), e.g., prepd. from 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(methylethyl)phenyl acetate in 3-steps, with NaNO2/HCl afforded IV.HCL (X = NO) in 82% yield. Compds. I, II, III, etc., donate, transfer or release nitric oxide or elevate levels of endogenous endothelium-derived relaxing factor, and are useful for treatment of sexual dysfunctions in males and females. In erectile response of anesthetized rabbits (2.5 kg), S-nitrosoglutathione, e.g., prepd. from glutathione and NaNO2/HCl, at 500 μg dosage was able to induce near maximal response relative to the std. dose of pap/phent/PGE1.
IT 90402-40-7D, Abanoquil, nitrated or nitrosylated derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of nitrosated and nitrosylated α-adrenergic receptor antagonists for the treatment of sexual dysfunction)
RN 90402-40-7 CA
CN 4-Quinolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



L13 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 135:344472 CA
TITLE: Preparation of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme
INVENTOR(S): Iwanowicz, Edwin J.; Watterson, Scott H.; Dhar, T. G. Murali; Pitts, William J.; Gu, Henry H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081340	A2	20011101	WO 2001-US12900	20010419
<--				
WO 2001081340	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2407370	A1	20011101	CA 2001-2407370	20010419
<--				
EP 1276739	A2	20030122	EP 2001-928708	20010419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531205	T	20031021	JP 2001-578430	20010419
US 2002040022	A1	20020404	US 2001-840503	20010423
US 6919335	B2	20050719		
PRIORITY APPLN. INFO.:			US 2000-199420P	P 20000424
			WO 2001-US12900	W 20010419

OTHER SOURCE(S): MARPAT 135:344472
GI



I



II

AB Title compds. I [wherein X1 = CO, SO, or SO2; X2 = CR3 or N; X3 = NH, O, or S; X4 = CR4 or N; X5 = CR5 or N; X6 = CR6 or N] were prepared were prepared

L13 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN (Continued)
as inosine monophosphate dehydrogenase (IMPDH) enzyme inhibitors. For example, acetalization of 4-nitro-2-methoxytoluene with AcOH (51%), redn. to the aldehyde (91%), and cycloaddn. with (p-tolylsulfonyl)methyl isocyanate gave 5-(4-nitro-2-methoxyphenyl)oxazole (84%), which was reduced to the amine (95%). Alkylation with Et benzoylacetate and cyclization afforded the 6-(5-oxazolyl)-4(1H)-quinolinone II. Thus, I are useful as therapeutic agents for IMPDH-assocd. disorders, such as allograft rejection (no data).
IT 371249-73-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-associated disorders)
RN 371249-73-9 CA
CN Quinoline, 2-(3-bromophenyl)-7-methoxy-4-(methoxymethoxy)-6-(5-oxazolyl)-(9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 135:272895 CA
TITLE: Preparation of Furanoisoquinoline derivatives as phosphodiesterase IV inhibitors
INVENTOR(S): Kawano, Yasuhiko; Matsumoto, Tatsumi; Uchikawa, Osamu;
Fujii, Nobuhiro; Tarui, Naoki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., USA
SOURCE: PCT Int. Appl., 620 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070746	A1	20010927	WO 2001-JP2277	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2404226	A1	20010927	CA 2001-2404226	20010322
AU 200139550	A	20011003	AU 2001-39550	20010322
EP 1270577	A1	20030102	EP 2001-914191	20010322
EP 1270577	B1	20061206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 347557	T	20061215	AT 2001-914191	20010322
JP 2001335579	A	20011204	JP 2001-84210	20010323
US 2004092582	A1	20040513	US 2002-239439	20020920
US 6924292	B2	20050802		
PRIORITY APPLN. INFO.:			JP 2000-87121 A	20000323
			WO 2001-JP2277 W	20010322

OTHER SOURCE(S): CASREACT 135:272895; MARPAT 135:272895
GI

L13 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN (Continued)



I

AB Title compds. [I; R1 = C6H5, 4-HOC6H4, 1-naphthyl, 4-CH3OC6H4, 2-CH3OC6H4, 4-NH2C6H4, 4-C6H5C6H4, 4-BrC6H4, CH3, C6H5CO, 3-CH3SCH2CONHC6H4, 3-CH3OCOC6H4, 3-NH2C(CH3)2CONHC6H4, 3-furyl, 3-HOCCC6H4, 2-chloro-4-pyridyl, 3-CH3CH2OCOC6H4, 4-pyridylethylaminocarbonyl; R2 = CH3, CH2Br, CH3CH2, H, CH3COO; R3 = CH3, H; R2R3 = (CH2)5; R4 = H, CH2N(CH3)2, CH2SC6H5, CH2C(:CH2)CH3, CH2NHCOCH3, CH3OCH2, CH2OH, CH2F, CH2COOH, CH2CN; R5 = Cl, OCH3, CON(CH3)2, CH3O, H, CH3CH2O, NH2, CHONH, CH3SO2NH, NH2CONH, CH3CH2S, CH3; R6 = CH3, H, CH3CH; R7 = CH3, H, CH3CH2; R6R7 = (CH2)5; R8 = H, CH3; R9 = H, CH3; Y = CH2, CHOH, C:O, C(CH3)2; X = electron pair, O, S; n = 0, 1] and salts are prepared as phosphodiesterase IV inhibitors. Title compds. are useful as preventives and remedies for diseases caused by inflammation, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, autoimmune disease and diabetes. Thus, the title compound I (R6 = CH3; R7 = CH3; R2 = CH3; R3 = CH3; X = O; R5 = CH3; n = 0; R9 = H; R8 = H; R1 = 3-CH3S:OCH2CONHC6H4) was prepared and biol. tested.

IT 363185-58-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of furano-isoquinoline deriva. as phosphodiesterase IV inhibitors)

RN 363185-58-4 CA
CN 3-Pyridinecarboxamide, 1,6-dihydro-1-(4-methyl-2-quinolinyl)-6-oxo- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN (Continued)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 134:178473 CA
TITLE: Preparation process of quinoline compounds as cGMP-specific phosphodiesterase inhibitors
INVENTOR(S): Umeda, Nobuhiro; Ito, Kunihito; Uchida, Seiichi; Shiinoki, Yasuyuki
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012608	A1	20010222	WO 2000-JP5497	20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 1999-231347 A	19990818

OTHER SOURCE(S): MARPAT 134:178473
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Novel quinoline compds. [I; R1 represents nitro, cyano, halogeno, etc.; n is 0 or an integer from 1 to 4; R2 and R3 represent hydrogene, etc.; R4 represents hydrogen, C1-6 alkyl, optionally substituted Ph, an optionally substituted saturated or unsatd. heterocycle, etc.; and R5 represents an optionally substituted saturated or unsatd. heterocycle bonded to the quinoline ring via a carbon atom in the cycle] and pharmaceutically acceptable salts are prepared and are useful as cGMP-specific phosphodiesterase (PDE) inhibitors . Thus, the title compound II was prepared and tested.

IT 324757-81-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation process of quinoline compds. as cGMP-specific phosphodiesterase inhibitors)

RN 324757-81-5 CA
CN 4-Quinolinamine, 6-chloro-N-[(3-chloro-4-methoxyphenyl)methyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L13 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN (Continued)

US 2006142282	A1	20060629	US 2006-339919		20060125
PRIORITY APPLN. INFO.:			US 1997-69741P	P	19971216
			WO 1998-IB1723	W	19981029
			US 1999-367169	B1	19991112
			US 2002-255538	A3	20020925

OTHER SOURCE(S): MARPAT 131:49481

AB The invention relates to the treatment of erectile dysfunction with a combination of (1) a compound selected from α-adrenergic receptor antagonists and (2) a compound selected from agents which elevate cGMP levels. Sildenafil or a pharmaceutically acceptable salt thereof is preferred as the cGMP PDE elevator. Also included are compns. and kits comprising such impotence treating compds. For example, an oral composition contains the combination of doxazosin mesylate and sildenafil citrate.

IT 90402-40-7, Abanoquil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(impotence treatment with α-adrenergic antagonists and cGMP level elevators)

RN 90402-40-7 CA

CN 4-Quinolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



L13 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 131:49481 CA
TITLE: Combination effective for the treatment of impotence
INVENTOR(S): Wyllie, Michael Grant
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930697	A2	19990624	WO 1998-IB1723	19981029
WO 9930697	A3	19990826		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2314993	A1	19990624	CA 1998-2314993	19981029
AU 9894558	A	19990705	AU 1998-94558	19981029
AU 759825	B2	20030501		
EP 1037616	A2	20000927	EP 1998-947741	19981029
EP 1037616	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
BR 9813699	A	20001010	BR 1998-13699	19981029
TR 200001733	T2	20001121	TR 2000-200001733	19981029
HU 200100705	A2	20010828	HU 2001-705	19981029
HU 200100705	A3	20011228		
JP 2002508315	T	20020319	JP 2000-538680	19981029
NZ 504487	A	20021126	NZ 1998-504487	19981029
AT 318602	T	20060315	AT 1998-947741	19981029
ES 2258300	T3	20060816	ES 1998-947741	19981029
AP 915	A	20001218	AP 1998-1414	19981210
W: BW, GM, KE, MW, UG, ZM, ZW				
ZA 9811507	A	20000619	ZA 1998-11507	19981215
BG 104528	A	20010228	BG 2000-104528	20000613
NO 2000003065	A	20000815	NO 2000-3065	20000615
HR 2000000407	A1	20001031	HR 2000-407	20000616

L13 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 119:203427 CA
TITLE: Preparation of N-containing heterocyclic compounds as phosphodiesterase inhibitors.
INVENTOR(S): Takase, Yasutaka; Watanabe, Nobuhisa; Matsui, Makoto; Ikuta, Hironori; Kimura, Teiji; Saeki, Takao; Adachi, Hideyuki; Tokumura, Tadakazu; Mochida, Hisatoshi; et al.
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9307124	A1	19930415	WO 1992-JP1258	19920930
W: AU, CA, FI, HU, JP, KR, NO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
ZA 9207465	A	19930413	ZA 1992-7465	19920929
CN 1071164	A	19930421	CN 1992-110792	19920929
AU 9226851	A	19930503	AU 1992-26851	19920930
AU 668363	B2	19960502		
EP 607439	A1	19940727	EP 1992-920913	19920930
EP 607439	B1	20020109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
HU 70854	A2	19951128	HU 1994-910	19920930
JP 2818487	B2	19981030	JP 1993-506780	19920930
JP 2000264885	A	20000926	JP 2000-70142	19920930
JP 3477138	B2	20031210		
JP 2000273089	A	20001003	JP 2000-70138	19920930
JP 3481900	B2	20031222		
AT 211734	T	20020115	AT 1992-920913	19920930
US 5576322	A	19961119	US 1994-196110	19940218
FI 9401417	A	19940325	FI 1994-1417	19940325
NO 9401101	A	19940530	NO 1994-1101	19940325
US 5693652	A	19971202	US 1995-408867	19950323
JP 10095776	A	19980414	JP 1997-195696	19970722
JP 3081172	B2	20000828		
US 5801180	A	19980901	US 1997-904260	19970731
JP 2000264877	A	20000926	JP 2000-70130	20000314
JP 3671131	B2	20050713		

L13 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN (Continued)

PRIORITY APPLN. INFO.: JP 1991-320853 A 19910930
JP 1993-506780 A3 19920930
JP 1997-195696 A3 19920930
WO 1992-JP1258 A 19920930
US 1994-196110 A3 19940218
US 1995-408867 A3 19950323

OTHER SOURCE(S): MARPAT 119:203427

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R1-R4 = H, halo, (halo)alkyl, (un)substituted cycloalkyl, alkoxy, etc.; R5 = H, OH, hydrazino, alkyl, (un)substituted cycloalkyl, alkoxy, etc.; R6 = H, halo, OH, cyano, alkyl, alkoxy, alkenyl, etc.; A = benzene ring, pyridine ring, cyclohexane ring; B = pyridine ring, pyrimidine ring, imidazole ring], useful for treatment of ischemia, heart attack, hypertension, cardiac insufficiency, and asthma (no data), are prepared E.g., a mixture of 4-hydroxy-6-carbamoylquinazoline, SOCl2, and POCl3 was reflexed for 20 h to give 4-chloro-6-cyanoquinazoline. 4-(4-Methoxybenzyl)amino-6,7,8-trimethoxyquinazoline (also prepared) had an IC50 of 1.0 μM against phosphodiesterase in an in vitro study.

IT 150453-90-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for phosphodiesterase inhibitors)

RN 150453-90-0 CA

CN 4-Piperidinecarboxylic acid, 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinolinyl]-, ethyl ester (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 14:15:14 ON 03 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 14:15:29 ON 03 MAY 2007
L1             STRUCTURE UPLOADED
L2          50 S L1 SAM
L3      254513 S L1 FULL

     FILE 'CA' ENTERED AT 14:15:57 ON 03 MAY 2007
L4       70217 S L3
L5       56103 S L4 AND PY<2002
L6       29448 S PDE? OR PHOSPHODIESTERASE?
L7         109 S L6 AND L5

     FILE 'REGISTRY' ENTERED AT 14:18:44 ON 03 MAY 2007
L8             STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 14:19:15 ON 03 MAY 2007
L9             STRUCTURE UPLOADED
L10      85771 S L9 FULL

     FILE 'CA' ENTERED AT 14:21:01 ON 03 MAY 2007
L11       4344 S L10
L12       3529 S L11 AND PY<2002
L13          6 S L12 AND L6

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:22:12 ON 03 MAY 2007
```